Monograph
S01JA01 - Fluorescein |
Propably not porphyrinogenic |
PNP |
Rationale
Fluorescein is probably not metabolised by CYP. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Fluorescein sodium is a water-soluble synthetic salt with fluorescent properties.
Therapeutic characteristics
Fluorescein is used both as a topical application (eye drops) and as an intravenous injection. Used topically, fluorescein stains damaged cornea and disrupted ocular fluids and is applied to the eye for the detection of corneal lesions and foreign bodies and to aid the fitting of hard contact lenses. It is also used in various other diagnostic ophthalmic procedures. The injection formulation is used in ophthalmic angiography and angioscopy.
Common side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmacokinetics
After injection fluorescein undergoes rapid metabolism to fluorescein monoglucuronide and is eliminated manly via renal excretion. Half-life is less than one hour.
Probably no CYP metabolism, and fluorescein is not listed as an inducer or inhibitor of CYP (Rendic 2002, Zhou 2008)
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.
|
|
| 2. | Zhou, S.F. Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4. Current Drug Metabolism 2008; 9: 310-322.
|
18473749 |
| * | Drug reference publications | |
| 3. | DrugBank. Fluorescein.
|
|
| 4. | Sweetman SC, editor. Martindale: The complete drug reference. Fluorescein. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 5. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Anatera.
|
|
| * | Other sources | |
| 6. | Swedish National Formulary. FASS. Fluorecite. www.fass.se (product leaflet).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland© NAPOS 2024